What is William Blair’s Estimate for FibroGen Q1 Earnings?

FibroGen, Inc. (NASDAQ:FGEN) – William Blair issued their Q1 2025 earnings estimates for shares of FibroGen in a report released on Tuesday, March 18th. William Blair analyst A. Hsieh expects that the biopharmaceutical company will post earnings of $0.02 per share for the quarter. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. William Blair also issued estimates for FibroGen’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.88) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.72) EPS.

A number of other brokerages have also recently issued reports on FGEN. StockNews.com started coverage on shares of FibroGen in a research report on Friday, March 14th. They issued a “hold” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of FibroGen in a report on Tuesday.

FibroGen Price Performance

Shares of NASDAQ FGEN opened at $0.36 on Thursday. The firm has a market cap of $36.05 million, a price-to-earnings ratio of -0.29 and a beta of 0.82. The stock’s fifty day moving average price is $0.50 and its two-hundred day moving average price is $0.43. FibroGen has a one year low of $0.18 and a one year high of $2.80.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $3.14 million during the quarter, compared to analyst estimates of $24.91 million.

Institutional Trading of FibroGen

Several large investors have recently made changes to their positions in FGEN. Geode Capital Management LLC boosted its holdings in shares of FibroGen by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after purchasing an additional 32,884 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in FibroGen by 430.7% in the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock valued at $668,000 after buying an additional 1,358,194 shares in the last quarter. FMR LLC grew its position in FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 68,569 shares during the last quarter. Franklin Street Advisors Inc. NC raised its stake in FibroGen by 100.0% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Two Sigma Investments LP raised its stake in FibroGen by 19.6% during the fourth quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock worth $320,000 after acquiring an additional 98,888 shares in the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.